Transgene (Paris:TNG) today announced its financial reporting dates for 2019:
|2018 Fiscal Year Results|
|First Quarter 2019 Financial Results|
WANT TO BUILD A FINANCIAL EMPIRE?
Subscribe to the Global Banking & Finance Review Newsletter for FREE Get Access to Exclusive Reports to Save Time & Money
By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
|Annual Shareholders’ Meeting|
|First Half 2019 Financial Results|
|Third Quarter 2019 Financial Results|
About Transgene Transgene (Euronext: TNG) is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgenes programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Companys lead clinical-stage programs are: TG4010, a therapeutic vaccine against non-small cell lung cancer, Pexa-Vec, an oncolytic virus against liver cancer, and TG4001, a therapeutic vaccine against HPV-positive head and neck cancers. The Company has several other programs in clinical development, including TG1050 (a therapeutic vaccine for the treatment of chronic hepatitis B) and TG6002 (an oncolytic virus for the treatment of solid tumors). With its proprietary Invir.IO„¢, Transgene builds on its expertise in viral vectors engineering to design a new generation of multifunctional oncolytic viruses. myvac„¢, an individualized MVA-based immunotherapy platform designed to integrate neoantigens, completes this innovative research portfolio. Additional information about Transgene is available at www.transgene.fr. Follow us on Twitter: @TransgeneSA
Jean-Philippe Del/Lucie Larguier
(0)3 88 27 11 21
Citigate Dewe Rogerson
Dible/Marine Perrier/Sylvie Berrebi
+44 (0)20 7638 9571